Last reviewed · How we verify
Hormone Replacement Therapy and Etidronate
This combination therapy replaces deficient hormones while simultaneously inhibiting bone resorption to maintain skeletal integrity.
This combination therapy replaces deficient hormones while simultaneously inhibiting bone resorption to maintain skeletal integrity. Used for Menopausal symptoms and osteoporosis prevention in postmenopausal women.
At a glance
| Generic name | Hormone Replacement Therapy and Etidronate |
|---|---|
| Sponsor | British Thoracic Society |
| Drug class | Hormone replacement therapy combined with bisphosphonate |
| Target | Estrogen receptor (HRT component); bone hydroxyapatite and osteoclast function (etidronate component) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Bone Health |
| Phase | FDA-approved |
Mechanism of action
Hormone Replacement Therapy (HRT) restores estrogen and/or progestin levels to alleviate menopausal symptoms and support bone health. Etidronate is a bisphosphonate that binds to bone mineral and inhibits osteoclast-mediated bone resorption, thereby reducing bone loss and fracture risk. Together, they address both symptomatic relief and bone preservation in postmenopausal women.
Approved indications
- Menopausal symptoms and osteoporosis prevention in postmenopausal women
Common side effects
- Breast tenderness
- Vaginal bleeding or spotting
- Nausea
- Headache
- Gastrointestinal upset (etidronate-related)
- Musculoskeletal pain
Key clinical trials
- HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: